Drugs for COVID-19: far beyond chloroquine (clinical trials for SARS-CoV-2 coronavirus)

• Autor(a) principal: Quintella, Cristina M.
• Data de Publicação: 2020
• Outros Autores: Silva, Lucilia Abreu Cabral e, Quintella, Heitor da Mata, Silva, Gustavo Henrique Ramos, Silva, Sávio Carlos Rodrigues da, Uchoa, Sílvia Beatriz Beger, Mata, Pedro Miguel de Assis Lopes Tavares da
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Cadernos de Prospecção (Online)
• Texto Completo: https://periodicos.ufba.br/index.php/nit/article/view/36815
• topic: níveis de maturidade tecnológica; TRL; vírus; pandemias; Terapias; Avaliação de tecnologia.; Technological Maturity Levels (TRL); Viruses; Pandemics; Therapies; Technology Assessment.

This work analyzes the drugs used for patients with COVID-19 which are undergoing clinical trials and that go well beyond chloroquine. The data were obtained from the World Health Organization's International Clinical Trials Registration Platform. Geodistribution shows concentration in China, and only 5% of transnational partnerships. Clinical tests are concentrated in intermediate phases II and III. The classes of drugs go far beyond antimalarials, which have become popularly known, also comprising antivirals, anti-inflammatories, antibiotics, anticoagulants, antibodies, antifibrotics, antitumor agents, calcium channel blockers, corticosteroids, immunomodulators, immunosuppressants, enzyme inhibitors, mucolytics, vasoconstrictors and vasodilators, vitamins and mineral salts. The most tested antivirals are Ritonavir, Remdesivir, Lopinavir, Favipiravir and Arbidol, as well as their associations. Several tests combine antimalarials, antivirals and immunomodulators, the most studied being Favipiravir and Lopinavir associated with Ritonavir, Methylprednisolone, Remdesivir, Tocilizumab, Chloroquine and Hydroxychloroquine.